BeiGene News
-
February 26, 2021BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
-
February 25, 2021BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results
BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results
-
February 17, 2021Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
-
February 17, 2021BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia
-
January 27, 2021BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
-
January 25, 2021EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China
EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for SYLVANT® (Siltuximab for Injection) in China
- BeiGene Facts
- 2010Founded
- NASDAQ: BGNE
HKEX: 06160Listings - 8Internally Developed
Clinical Candidates - 6Marketed
Products
in China - 1Approved
Product
in the U.S. - 5400+Global Team
Partnering
Partnerships that Extend Around the Globe
BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.
Our Patients
Our Commitment to Patients
At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.